Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published May 1, 2012 Previous issue | Next issue

  • Volume 122, Issue 5
Go to section:
  • Editorial
  • Science in Medicine
  • Conversations with Giants in Medicine
  • Obituary
  • Hindsight
  • The Attending Physician
  • Commentaries
  • Research Articles
  • Corrigenda

On the cover: Renal failure in multiple myeloma

A common renal complication of multiple myeloma is cast nephropathy, which results from the co-precipitate of monoclonal immunoglobulin free light chains (FLC) with Tamm-Horsfall glycoproteins (THP) in the lumen of the distal nephron. In this issue, Ying and colleagues describe a cyclized competitor peptide that inhibits the binding of FLC to THP (page 1777) and could represent an approach to the management of renal failure during multiple myeloma.
Image credit: Shutterstock, Inc. Copyright: Denis Barbulat.
Editorial
Constitutively, pathologically, profoundly
Ushma S. Neill
Ushma S. Neill
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1585-1585. https://doi.org/10.1172/JCI64042.
View: Text | PDF

Constitutively, pathologically, profoundly

  • Text
  • PDF
Abstract

There are a hundred reasons to love the JCI and I have loved it truly, madly, and deeply for the last nine years. Alas, I’ll have to learn to love the Journal from afar, as tomorrow marks my last official day as Executive Editor. To quote Chaucer, “There is an end to everything, to good things as well.”

Authors

Ushma S. Neill

×
Science in Medicine
Uncovering the role of genomic “dark matter” in human disease
Lance Martin, Howard Y. Chang
Lance Martin, Howard Y. Chang
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1589-1595. https://doi.org/10.1172/JCI60020.
View: Text | PDF

Uncovering the role of genomic “dark matter” in human disease

  • Text
  • PDF
Abstract

The human genome encodes thousands of long noncoding RNAs (lncRNAs). Although most remain functionally uncharacterized biological “dark matter,” lncRNAs have garnered considerable attention for their diverse roles in human biology, including developmental programs and tumor suppressor gene networks. As the number of lncRNAs associated with human disease grows, ongoing research efforts are focusing on their regulatory mechanisms. New technologies that enable enumeration of lncRNA interaction partners and determination of lncRNA structure are well positioned to drive deeper understanding of their functions and involvement in pathogenesis. In turn, lncRNAs may become targets for therapeutic intervention or new tools for biotechnology.

Authors

Lance Martin, Howard Y. Chang

×
Conversations with Giants in Medicine
A conversation with Robert Lefkowitz, Joseph Goldstein, and Michael Brown
Ushma S. Neill, Howard A. Rockman
Ushma S. Neill, Howard A. Rockman
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1586-1587. https://doi.org/10.1172/JCI64244.
View: Text | PDF

A conversation with Robert Lefkowitz, Joseph Goldstein, and Michael Brown

  • Text
  • PDF
Abstract

Authors

Ushma S. Neill, Howard A. Rockman

×
Obituary
Lloyd J. Old — a scientific concertmaster
Ellen Puré
Ellen Puré
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1588-1588. https://doi.org/10.1172/JCI64110.
View: Text | PDF

Lloyd J. Old — a scientific concertmaster

  • Text
  • PDF
Abstract

Authors

Ellen Puré

×
Hindsight
Degranulation deconstructed
Robert L. Baehner, Morris J. Karnovsky
Robert L. Baehner, Morris J. Karnovsky
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1596-1597. https://doi.org/10.1172/JCI62990.
View: Text | PDF

Degranulation deconstructed

  • Text
  • PDF
Abstract

Pediatricians first described the clinical features of chronic granulomatous disease (CGD) in 1959. Almost a decade later, in a collaborative effort that crossed disciplines, we participated in the discoveries that defined the cellular deficiencies of CGD, specifically finding that improper degranulation of leukocytes did not explain their failure to fight pathogens, rather that the fundamental defect was due to problems in the unique NADPH oxidase system of phagocytizing leukocytes. In the years that followed, the subunit components and structure of NADPH oxidase and their translocation during leukocyte phagocytosis to form the active enzyme were well described, leading to the identification of the component genes, the mapping of their chromosomal locations, and their subsequent cloning. This remarkable progress has led to effective therapies, including bone marrow transplants and gene therapy, that would have been unimaginable when we began.

Authors

Robert L. Baehner, Morris J. Karnovsky

×
The Attending Physician
How much vitamin D should I take?
Cathleen S. Colón-Emeric, Kenneth W. Lyles
Cathleen S. Colón-Emeric, Kenneth W. Lyles
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1598-1599. https://doi.org/10.1172/JCI62966.
View: Text | PDF

How much vitamin D should I take?

  • Text
  • PDF
Abstract

Clinical vignette: A 68-year-old woman consults you after a recent bone mineral density screening revealed osteopenia, total hip T score of –1.8. Further evaluation shows her only other abnormal lab value is a serum 25-hydroxy­vitamin D [25(OH)D] level of 13 ng/ml (normal 30–80). You find no evidence of malabsorption. What vitamin D supplement regimen should you recommend to reduce her risk of fractures?

Authors

Cathleen S. Colón-Emeric, Kenneth W. Lyles

×
Commentaries
Gene therapy: too much splice can spoil the dish
Didier Trono
Didier Trono
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1600-1602. https://doi.org/10.1172/JCI63066.
View: Text | PDF

Gene therapy: too much splice can spoil the dish

  • Text
  • PDF
Abstract

The use of integrating vectors for gene therapy — required for stable correction of gene expression — carries the risk of insertional mutagenesis, which can lead to activation of a tumorigenic program. In this issue of the JCI, Moiani et al. and Cesana et al. investigate how viral vectors can induce aberrant splicing, resulting in chimeric cellular-viral transcripts. The finding that this is a general phenomenon is concerning, but some of their results do suggest approaches for the development of safeguards in gene therapy vector design.

Authors

Didier Trono

×

Epidermal Langerhans cells tune skin reactivity to contact allergens
Mark C. Udey
Mark C. Udey
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1602-1605. https://doi.org/10.1172/JCI63190.
View: Text | PDF

Epidermal Langerhans cells tune skin reactivity to contact allergens

  • Text
  • PDF
Abstract

Allergic contact dermatitis is a common disorder that has fascinated dermatologists and immunologists for decades. Extensive studies of contact sensitivity reactions in mice established a mechanistic paradigm that has been revisited in recent years, and the involvement of Langerhans cells (LCs), a population of epidermal dendritic cells, in immune responses to epicutaneously applied antigens has been questioned. In this issue of the JCI, Gomez de Agüero et al. describe an elegant series of experiments that implicate LCs in tolerance induction, positioning these cells as key regulators of immunologic barrier function.

Authors

Mark C. Udey

×

Treating myeloma cast nephropathy without treating myeloma
Nelson Leung
Nelson Leung
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1605-1608. https://doi.org/10.1172/JCI63248.
View: Text | PDF

Treating myeloma cast nephropathy without treating myeloma

  • Text
  • PDF
Abstract

Cast nephropathy is the result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein (THP). It is a hallmark of multiple myeloma that has significant consequences. Treatment strategies in the past focused on reduction of serum FLC by control of the myeloma. In this issue, Ying et al. report on their successful synthesis of a cyclized competitor peptide that blocks the binding of FLC to THP. In animal studies, this cyclized peptide was capable of reducing cast formation and kidney injury, representing a novel treatment strategy for cast nephropathy that does not depend on the responsiveness of the myeloma to chemotherapy.

Authors

Nelson Leung

×

NADPH oxidase regulates efficacy of vaccination in aspergillosis
George S. Deepe Jr.
George S. Deepe Jr.
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1608-1611. https://doi.org/10.1172/JCI63417.
View: Text | PDF

NADPH oxidase regulates efficacy of vaccination in aspergillosis

  • Text
  • PDF
Abstract

Invasive aspergillosis is often a consequence of immune suppression, and accumulating evidence points to a role for adaptive immunity. Hence, it may be possible to manipulate the adaptive immune system to enhance protective immunity in at-risk individuals. In this issue of the JCI, De Luca and colleagues describe the ontogeny of adaptive immune responses to murine aspergillosis infection in relation to vaccination. Their thought-provoking findings reveal the complexities of vaccine-induced immunity and could be used to improve vaccine efficacy.

Authors

George S. Deepe Jr.

×

Enhancing immune responses to limit chronic immune activation during SIV
Jacob D. Estes
Jacob D. Estes
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1611-1614. https://doi.org/10.1172/JCI63389.
View: Text | PDF

Enhancing immune responses to limit chronic immune activation during SIV

  • Text
  • PDF
Abstract

The persistent immune activation that is typical of HIV-1 and SIV infection results in exhaustion and dysfunction of T and B cells; in T cells, this is marked by increased expression and signaling through the inhibitory receptor programmed death–1 (PD-1). Targeting this exhaustion pathway could result in improved antiviral immune responses, but there have been concerns that it would also lead to increased inflammation and immunopathology. In this issue of the JCI, Dyavar Shetty et al. demonstrate that blocking PD-1 actually reduced proinflammatory responses and improved immunity in the gut of SIV-infected rhesus macaques, suggesting that this might have therapeutic potential to prevent opportunistic infections in HIV-infected patients.

Authors

Jacob D. Estes

×
Research Articles
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice
Santiago Zelenay, … , David Sancho, Caetano Reis e Sousa
Santiago Zelenay, … , David Sancho, Caetano Reis e Sousa
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1615-1627. https://doi.org/10.1172/JCI60644.
View: Text | PDF

The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice

  • Text
  • PDF
Abstract

DNGR-1 (CLEC9A) is a receptor for necrotic cells required by DCs to cross-prime CTLs against dead cell antigens in mice. It is currently unknown how DNGR-1 couples dead cell recognition to cross-priming. Here we found that DNGR-1 did not mediate DC activation by dead cells but rather diverted necrotic cell cargo into a recycling endosomal compartment, favoring cross-presentation to CD8+ T cells. DNGR-1 regulated cross-priming in non-infectious settings such as immunization with antigen-bearing dead cells, as well as in highly immunogenic situations such as infection with herpes simplex virus type 1. Together, these results suggest that DNGR-1 is a dedicated receptor for cross-presentation of cell-associated antigens. Our work thus underscores the importance of cross-priming in immunity and indicates that antigenicity and adjuvanticity can be decoded by distinct innate immune receptors. The identification of specialized receptors that regulate antigenicity of virus-infected cells reveals determinants of antiviral immunity that might underlie the human response to infection and vaccination.

Authors

Santiago Zelenay, Anna M. Keller, Paul G. Whitney, Barbara U. Schraml, Safia Deddouche, Neil C. Rogers, Oliver Schulz, David Sancho, Caetano Reis e Sousa

×

The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice
Salvador Iborra, … , Caetano Reis e Sousa, David Sancho
Salvador Iborra, … , Caetano Reis e Sousa, David Sancho
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1628-1643. https://doi.org/10.1172/JCI60660.
View: Text | PDF

The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice

  • Text
  • PDF
Abstract

In order to prime T cells, DCs integrate signals emanating directly from pathogens and from their noxious action on the host. DNGR-1 (CLEC9A) is a DC-restricted receptor that detects dead cells. Therefore, we investigated the possibility that DNGR-1 affects immunity to cytopathic viruses. DNGR-1 was essential for cross-presentation of dying vaccinia virus–infected (VACV-infected) cells to CD8+ T cells in vitro. Following injection of VACV or VACV-infected cells into mice, DNGR-1 detected the ligand in dying infected cells and mediated cross-priming of anti-VACV CD8+ T cells. Loss of DNGR-1 impaired the CD8+ cytotoxic response to VACV, especially against those virus strains that are most dependent on cross-presentation. The decrease in total anti-VACV CTL activity was associated with a profound increase in viral load and delayed resolution of the primary lesion. In addition, lack of DNGR-1 markedly diminished protection from infection induced by vaccination with the modified vaccinia Ankara (MVA) strain. DNGR-1 thus contributes to anti-VACV immunity, following both primary infection and vaccination. The non-redundant ability of DNGR-1 to regulate cross-presentation of viral antigens suggests that this form of regulation of antiviral immunity could be exploited for vaccination.

Authors

Salvador Iborra, Helena M. Izquierdo, María Martínez-López, Noelia Blanco-Menéndez, Caetano Reis e Sousa, David Sancho

×

Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation
Frederic Bibollet-Ruche, … , Beatrice H. Hahn, Frank Kirchhoff
Frederic Bibollet-Ruche, … , Beatrice H. Hahn, Frank Kirchhoff
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1644-1652. https://doi.org/10.1172/JCI61429.
View: Text | PDF

Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation

  • Text
  • PDF
Abstract

SIVs infecting wild-living apes in west central Africa have crossed the species barrier to humans on at least four different occasions, one of which spawned the AIDS pandemic. Although the chimpanzee precursor of pandemic HIV-1 strains must have been able to infect humans, the capacity of SIVcpz strains to replicate in human lymphoid tissues (HLTs) is not known. Here, we show that SIVcpz strains from two chimpanzee subspecies are capable of replicating in human tonsillary explant cultures, albeit only at low titers. However, SIVcpz replication in HLT was significantly improved after introduction of a previously identified human-specific adaptation at position 30 in the viral Gag matrix protein. An Arg or Lys at this position significantly increased SIVcpz replication in HLT, while the same mutation reduced viral replication in chimpanzee-derived CD4+ T cells. Thus, naturally occurring SIVcpz strains are capable of infecting HLTs, the major site of HIV-1 replication in vivo. However, efficient replication requires the acquisition of a host-specific adaptation in the viral matrix protein. These results identify Gag matrix as a major determinant of SIVcpz replication fitness in humans and suggest a critical role in the emergence of HIV/AIDS.

Authors

Frederic Bibollet-Ruche, Anke Heigele, Brandon F. Keele, Juliet L. Easlick, Julie M. Decker, Jun Takehisa, Gerald Learn, Paul M. Sharp, Beatrice H. Hahn, Frank Kirchhoff

×

Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts
Arianna Moiani, … , Giuliana Ferrari, Fulvio Mavilio
Arianna Moiani, … , Giuliana Ferrari, Fulvio Mavilio
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1653-1666. https://doi.org/10.1172/JCI61852.
View: Text | PDF

Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts

  • Text
  • PDF
Abstract

Retroviral vectors integrate in genes and regulatory elements and may cause transcriptional deregulation of gene expression in target cells. Integration into transcribed genes also has the potential to deregulate gene expression at the posttranscriptional level by interfering with splicing and polyadenylation of primary transcripts. To examine the impact of retroviral vector integration on transcript splicing, we transduced primary human cells or cultured cells with HIV-derived vectors carrying a reporter gene or a human β-globin gene under the control of a reduced-size locus-control region (LCR). Cells were randomly cloned and integration sites were determined in individual clones. We identified aberrantly spliced, chimeric transcripts in more than half of the targeted genes in all cell types. Chimeric transcripts were generated through the use of constitutive and cryptic splice sites in the HIV 5ι long terminal repeat and gag gene as well as in the β-globin gene and LCR. Compared with constitutively spliced transcripts, most aberrant transcripts accumulated at a low level, at least in part as a consequence of nonsense-mediated mRNA degradation. A limited set of cryptic splice sites caused the majority of aberrant splicing events, providing a strategy for recoding lentiviral vector backbones and transgenes to reduce their potential posttranscriptional genotoxicity.

Authors

Arianna Moiani, Ylenia Paleari, Daniela Sartori, Riccardo Mezzadra, Annarita Miccio, Claudia Cattoglio, Fabienne Cocchiarella, Maria Rosa Lidonnici, Giuliana Ferrari, Fulvio Mavilio

×

Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations
Daniela Cesana, … , Luigi Naldini, Eugenio Montini
Daniela Cesana, … , Luigi Naldini, Eugenio Montini
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1667-1676. https://doi.org/10.1172/JCI62189.
View: Text | PDF

Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations

  • Text
  • PDF
Abstract

Gamma-retroviral/lentiviral vectors (γRV/LV) with self-inactivating (SIN) long terminal repeats (LTRs) and internal moderate cellular promoters pose a reduced risk of insertional mutagenesis when compared with vectors with active LTRs. Yet, in a recent LV-based clinical trial for β-thalassemia, vector integration within the HMGA2 gene induced the formation of an aberrantly spliced mRNA form that appeared to cause clonal dominance. Using a method that we developed, cDNA linear amplification-mediated PCR, in combination with high-throughput sequencing, we conducted a whole transcriptome analysis of chimeric LV-cellular fusion transcripts in transduced human lymphoblastoid cells and primary hematopoietic stem/progenitor cells. We observed a surprising abundance of read-through transcription originating outside and inside the provirus and identified the vector sequences contributing to the aberrant splicing process. We found that SIN LV has a sharply reduced propensity to engage in aberrant splicing compared with that of vectors carrying active LTRs. Moreover, by recoding the identified vector splice sites, we reduced residual read-through transcription and demonstrated an effective strategy for improving vectors. Characterization of the mechanisms and genetic features underlying vector-induced aberrant splicing will enable the generation of safer vectors, with low impact on the cellular transcriptome.

Authors

Daniela Cesana, Jacopo Sgualdino, Laura Rudilosso, Stefania Merella, Luigi Naldini, Eugenio Montini

×

Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice
Ding Ai, … , Daniel J. Rader, Alan R. Tall
Ding Ai, … , Daniel J. Rader, Alan R. Tall
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1677-1687. https://doi.org/10.1172/JCI61248.
View: Text | PDF

Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice

  • Text
  • PDF
Abstract

Recent GWAS have identified SNPs at a human chromosom1 locus associated with coronary artery disease risk and LDL cholesterol levels. The SNPs are also associated with altered expression of hepatic sortilin-1 (SORT1), which encodes a protein thought to be involved in apoB trafficking and degradation. Here, we investigated the regulation of Sort1 expression in mouse models of obesity. Sort1 expression was markedly repressed in both genetic (ob/ob) and high-fat diet models of obesity; restoration of hepatic sortilin-1 levels resulted in reduced triglyceride and apoB secretion. Mouse models of obesity also exhibit increased hepatic activity of mammalian target of rapamycin complex 1 (mTORC1) and ER stress, and we found that administration of the mTOR inhibitor rapamycin to ob/ob mice reduced ER stress and increased hepatic sortilin-1 levels. Conversely, genetically increased hepatic mTORC1 activity was associated with repressed Sort1 and increased apoB secretion. Treating WT mice with the ER stressor tunicamycin led to marked repression of hepatic sortilin-1 expression, while administration of the chemical chaperone PBA to ob/ob mice led to amelioration of ER stress, increased sortilin-1 expression, and reduced apoB and triglyceride secretion. Moreover, the ER stress target Atf3 acted at the SORT1 promoter region as a transcriptional repressor, whereas knockdown of Atf3 mRNA in ob/ob mice led to increased hepatic sortilin-1 levels and decreased apoB and triglyceride secretion. Thus, in mouse models of obesity, induction of mTORC1 and ER stress led to repression of hepatic Sort1 and increased VLDL secretion via Atf3. This pathway may contribute to dyslipidemia in metabolic disease.

Authors

Ding Ai, Juan M. Baez, Hongfeng Jiang, Donna M. Conlon, Antonio Hernandez-Ono, Maria Frank-Kamenetsky, Stuart Milstein, Kevin Fitzgerald, Andrew J. Murphy, Connie W. Woo, Alanna Strong, Henry N. Ginsberg, Ira Tabas, Daniel J. Rader, Alan R. Tall

×

Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice
Yuan Zhang, … , David J. Mangelsdorf, Ira G. Schulman
Yuan Zhang, … , David J. Mangelsdorf, Ira G. Schulman
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1688-1699. https://doi.org/10.1172/JCI59817.
View: Text | PDF

Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice

  • Text
  • PDF
Abstract

Liver X receptors (LXRα and LXRβ) are important regulators of cholesterol and lipid metabolism, and their activation has been shown to inhibit cardiovascular disease and reduce atherosclerosis in animal models. Small molecule agonists of LXR activity are therefore of great therapeutic interest. However, the finding that such agonists also promote hepatic lipogenesis has led to the idea that hepatic LXR activity is undesirable from a therapeutic perspective. To investigate whether this might be true, we performed gene targeting to selectively delete LXRα in hepatocytes. Liver-specific deletion of LXRα in mice substantially decreased reverse cholesterol transport, cholesterol catabolism, and cholesterol excretion, revealing the essential importance of hepatic LXRα for whole body cholesterol homeostasis. Additionally, in a pro-atherogenic background, liver-specific deletion of LXRα increased atherosclerosis, uncovering an important function for hepatic LXR activity in limiting cardiovascular disease. Nevertheless, synthetic LXR agonists still elicited anti-atherogenic activity in the absence of hepatic LXRα, indicating that the ability of agonists to reduce cardiovascular disease did not require an increase in cholesterol excretion. Furthermore, when non-atherogenic mice were treated with synthetic LXR agonists, liver-specific deletion of LXRα eliminated the detrimental effect of increased plasma triglycerides, while the beneficial effect of increased plasma HDL was unaltered. In sum, these observations suggest that therapeutic strategies that bypass the liver or limit the activation of hepatic LXRs should still be beneficial for the treatment of cardiovascular disease.

Authors

Yuan Zhang, Sarah R. Breevoort, Jerry Angdisen, Mingui Fu, Daniel R. Schmidt, Sam R. Holmstrom, Steven A. Kliewer, David J. Mangelsdorf, Ira G. Schulman

×

Langerhans cells protect from allergic contact dermatitis in mice by tolerizing CD8+ T cells and activating Foxp3+ regulatory T cells
Mercedes Gomez de Agüero, … , Dominique Kaiserlian, Bertrand Dubois
Mercedes Gomez de Agüero, … , Dominique Kaiserlian, Bertrand Dubois
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1700-1711. https://doi.org/10.1172/JCI59725.
View: Text | PDF

Langerhans cells protect from allergic contact dermatitis in mice by tolerizing CD8+ T cells and activating Foxp3+ regulatory T cells

  • Text
  • PDF
Abstract

Allergic contact dermatitis is the most frequent occupational disease in industrialized countries. It is caused by CD8+ T cell–mediated contact hypersensitivity (CHS) reactions triggered at the site of contact by a variety of chemicals, also known as weak haptens, present in fragrances, dyes, metals, preservatives, and drugs. Despite the myriad of potentially allergenic substances that can penetrate the skin, sensitization is relatively rare and immune tolerance to the substance is often induced by as yet poorly understood mechanisms. Here we show, using the innocuous chemical 2,4-dinitrothiocyanobenzene (DNTB), that cutaneous immune tolerance in mice critically depends on epidermal Langerhans cells (LCs), which capture DNTB and migrate to lymph nodes for direct presentation to CD8+ T cells. Depletion and adoptive transfer experiments revealed that LCs conferred protection from development of CHS by a mechanism involving both anergy and deletion of allergen-specific CD8+ T cells and activation of a population of T cells identified as ICOS+CD4+Foxp3+ Tregs. Our findings highlight the critical role of LCs in tolerance induction in mice to the prototype innocuous hapten DNTB and suggest that strategies targeting LCs might be valuable for prevention of cutaneous allergy.

Authors

Mercedes Gomez de Agüero, Marc Vocanson, Fériel Hacini-Rachinel, Morgan Taillardet, Tim Sparwasser, Adrien Kissenpfennig, Bernard Malissen, Dominique Kaiserlian, Bertrand Dubois

×

PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques
Ravi Dyavar Shetty, … , Guido Silvestri, Rama Rao Amara
Ravi Dyavar Shetty, … , Guido Silvestri, Rama Rao Amara
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1712-1716. https://doi.org/10.1172/JCI60612.
View: Text | PDF Brief Report

PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques

  • Text
  • PDF
Abstract

Hyperimmune activation is a strong predictor of disease progression during pathogenic immunodeficiency virus infections and is mediated in part by sustained type I IFN signaling in response to adventitious microbial infection. The immune inhibitory receptor programmed death–1 (PD-1) regulates functional exhaustion of virus-specific CD8+ T cells during chronic infections, and in vivo PD-1 blockade has been shown to improve viral control of SIV. Here, we show that PD-1 blockade during chronic SIV infection markedly reduced the expression of transcripts associated with type I IFN signaling in the blood and colorectal tissue of rhesus macaques (RMs). The effect of PD-1 blockade on type I IFN signaling was durable and persisted even under conditions of high viremia. Reduced type I IFN signaling was associated with enhanced expression of some of the junction-associated genes in colorectal tissue and with a profound decrease in plasma LPS levels, suggesting a possible repair of gut-associated junctions and decreased microbial translocation into the blood. PD-1 blockade enhanced immunity to gut-resident pathogenic bacteria, control of gut-associated opportunistic infections, and survival of SIV-infected RMs. Our results suggest PD-1 blockade as a potential novel therapeutic approach to enhance combination antiretroviral therapy by suppressing hyperimmune activation in HIV-infected individuals.

Authors

Ravi Dyavar Shetty, Vijayakumar Velu, Kehmia Titanji, Steven E. Bosinger, Gordon J. Freeman, Guido Silvestri, Rama Rao Amara

×

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice
Tatiana Takiishi, … , Conny Gysemans, Chantal Mathieu
Tatiana Takiishi, … , Conny Gysemans, Chantal Mathieu
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1717-1725. https://doi.org/10.1172/JCI60530.
View: Text | PDF

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice

  • Text
  • PDF
Abstract

Current interventions for arresting autoimmune diabetes have yet to strike the balance between sufficient efficacy, minimal side effects, and lack of generalized immunosuppression. Introduction of antigen via the gut represents an appealing method for induction of antigen-specific tolerance. Here, we developed a strategy for tolerance restoration using mucosal delivery in mice of biologically contained Lactococcus lactis genetically modified to secrete the whole proinsulin autoantigen along with the immunomodulatory cytokine IL-10. We show that combination therapy with low-dose systemic anti-CD3 stably reverted diabetes in NOD mice and increased frequencies of local Tregs, which not only accumulated in the pancreatic islets, but also suppressed immune response in an autoantigen-specific way. Cured mice remained responsive to disease-unrelated antigens, which argues against excessive immunosuppression. Application of this therapeutic tool achieved gut mucosal delivery of a diabetes-relevant autoantigen and a biologically active immunomodulatory cytokine, IL-10, and, when combined with a low dose of systemic anti-CD3, was well tolerated and induced autoantigen-specific long-term tolerance, allowing reversal of established autoimmune diabetes. Therefore, we believe this method could be an effective treatment strategy for type 1 diabetes in humans.

Authors

Tatiana Takiishi, Hannelie Korf, Tom L. Van Belle, Sofie Robert, Fabio A. Grieco, Silvia Caluwaerts, Letizia Galleri, Isabella Spagnuolo, Lothar Steidler, Karolien Van Huynegem, Pieter Demetter, Clive Wasserfall, Mark A. Atkinson, Francesco Dotta, Pieter Rottiers, Conny Gysemans, Chantal Mathieu

×

Cooperation between Rb and Arf in suppressing mouse retinoblastoma
Karina Conkrite, … , Shizuo Mukai, David MacPherson
Karina Conkrite, … , Shizuo Mukai, David MacPherson
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1726-1733. https://doi.org/10.1172/JCI61403.
View: Text | PDF

Cooperation between Rb and Arf in suppressing mouse retinoblastoma

  • Text
  • PDF
Abstract

Retinoblastoma is a pediatric cancer that has served as a paradigm for tumor suppressor gene function. Retinoblastoma is initiated by RB gene mutations, but the subsequent cooperating mutational events leading to tumorigenesis are poorly characterized. We investigated what these additional genomic alterations might be using human retinoblastoma samples and mouse models. Array-based comparative genomic hybridization studies revealed deletions in the CDKN2A locus that include ARF and P16INK4A, both of which encode tumor suppressor proteins, in both human and mouse retinoblastoma. Through mouse genetic analyses, we found that Arf was the critical tumor suppressor gene in the deleted region. In mice, inactivation of one allele of Arf cooperated with Rb and p107 loss to rapidly accelerate retinoblastoma, with frequent loss of heterozygosity (LOH) at the Arf locus. Arf has been reported to exhibit p53-independent tumor suppressor roles in other systems; however, our results showed no additive effect of p53 and Arf coinactivation in promoting retinoblastoma. Moreover, p53 inactivation completely eliminated any selection for Arf LOH. Thus, our data reveal important insights into the p53 pathway in retinoblastoma and show that Arf is a key collaborator with Rb in retinoblastoma suppression.

Authors

Karina Conkrite, Maggie Sundby, David Mu, Shizuo Mukai, David MacPherson

×

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker
Partha Ray, … , Bruce A. Sullenger, Rebekah R. White
Partha Ray, … , Bruce A. Sullenger, Rebekah R. White
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1734-1741. https://doi.org/10.1172/JCI62385.
View: Text | PDF Technical Advance

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker

  • Text
  • PDF
Abstract

Most cases of pancreatic cancer are not diagnosed until they are no longer curable with surgery. Therefore, it is critical to develop a sensitive, preferably noninvasive, method for detecting the disease at an earlier stage. In order to identify biomarkers for pancreatic cancer, we devised an in vitro positive/negative selection strategy to identify RNA ligands (aptamers) that could detect structural differences between the secretomes of pancreatic cancer and non-cancerous cells. Using this molecular recognition approach, we identified an aptamer (M9-5) that differentially bound conditioned media from cancerous and non-cancerous human pancreatic cell lines. This aptamer further discriminated between the sera of pancreatic cancer patients and healthy volunteers with high sensitivity and specificity. We utilized biochemical purification methods and mass-spectrometric analysis to identify the M9-5 target as cyclophilin B (CypB). This molecular recognition–based strategy simultaneously identified CypB as a serum biomarker and generated a new reagent to recognize it in body fluids. Moreover, this approach should be generalizable to other diseases and complementary to traditional approaches that focus on differences in expression level between samples. Finally, we suggest that the aptamer we identified has the potential to serve as a tool for the early detection of pancreatic cancer.

Authors

Partha Ray, Kristy L. Rialon-Guevara, Emanuela Veras, Bruce A. Sullenger, Rebekah R. White

×

Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination
Dimitra Kiritsi, … , Leena Bruckner-Tuderman, Cristina Has
Dimitra Kiritsi, … , Leena Bruckner-Tuderman, Cristina Has
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1742-1746. https://doi.org/10.1172/JCI61976.
View: Text | PDF Brief Report

Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination

  • Text
  • PDF
Abstract

Spontaneous gene repair, also called revertant mosaicism, has been documented in several genetic disorders involving organs that undergo self-regeneration, including the skin. Genetic reversion may occur through different mechanisms, and in a single individual, the mutation can be repaired in various ways. Here we describe a disseminated pattern of revertant mosaicism observed in 6 patients with Kindler syndrome (KS), a genodermatosis caused by loss of kindlin-1 (encoded by FERMT1) and clinically characterized by patchy skin pigmentation and atrophy. All patients presented duplication mutations (c.456dupA and c.676dupC) in FERMT1, and slipped mispairing in direct nucleotide repeats was identified as the reversion mechanism in all investigated revertant skin spots. The sequence around the mutations demonstrated high propensity to mutations, favoring both microinsertions and microdeletions. Additionally, in some revertant patches, mitotic recombination generated areas with homozygous normal keratinocytes. Restoration of kindlin-1 expression led to clinically and structurally normal skin. Since loss of kindlin-1 severely impairs keratinocyte proliferation, we predict that revertant cells have a selective advantage that allows their clonal expansion and, consequently, the improvement of the skin condition.

Authors

Dimitra Kiritsi, Yinghong He, Anna M.G. Pasmooij, Meltem Onder, Rudolf Happle, Marcel F. Jonkman, Leena Bruckner-Tuderman, Cristina Has

×

CD14 and NFAT mediate lipopolysaccharide-induced skin edema formation in mice
Ivan Zanoni, … , Roberta Marzi, Francesca Granucci
Ivan Zanoni, … , Roberta Marzi, Francesca Granucci
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1747-1757. https://doi.org/10.1172/JCI60688.
View: Text | PDF

CD14 and NFAT mediate lipopolysaccharide-induced skin edema formation in mice

  • Text
  • PDF
Abstract

Inflammation is a multistep process triggered when innate immune cells — for example, DCs — sense a pathogen or injured cell or tissue. Edema formation is one of the first steps in the inflammatory response; it is fundamental for the local accumulation of inflammatory mediators. Injection of LPS into the skin provides a model for studying the mechanisms of inflammation and edema formation. While it is known that innate immune recognition of LPS leads to activation of numerous transcriptional activators, including nuclear factor of activated T cells (NFAT) isoforms, the molecular pathways that lead to edema formation have not been determined. As PGE2 regulates many proinflammatory processes, including swelling and pain, and it is induced by LPS, we hypothesized that PGE2 mediates the local generation of edema following LPS exposure. Here, we show that tissue-resident DCs are the main source of PGE2 and the main controllers of tissue edema formation in a mouse model of LPS-induced inflammation. LPS exposure induced expression of microsomal PGE synthase-1 (mPGES-1), a key enzyme in PGE2 biosynthesis. mPGES-1 activation, PGE2 production, and edema formation required CD14 (a component of the LPS receptor) and NFAT. Therefore, tissue edema formation induced by LPS is DC and CD14/NFAT dependent. Moreover, DCs can regulate free antigen arrival at the draining lymph nodes by controlling edema formation and interstitial fluid pressure in the presence of LPS. We therefore suggest that the CD14/NFAT/mPGES-1 pathway represents a possible target for antiinflammatory therapies.

Authors

Ivan Zanoni, Renato Ostuni, Simona Barresi, Marco Di Gioia, Achille Broggi, Barbara Costa, Roberta Marzi, Francesca Granucci

×

Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice
Lee J. Quinton, … , Avrum Spira, Joseph P. Mizgerd
Lee J. Quinton, … , Avrum Spira, Joseph P. Mizgerd
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1758-1763. https://doi.org/10.1172/JCI59408.
View: Text | PDF Brief Report

Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice

  • Text
  • PDF
Abstract

The acute phase response is an evolutionarily conserved reaction in which physiological stress triggers the liver to remodel the blood proteome. Although thought to be involved in immune defense, the net biological effect of the acute phase response remains unknown. As the acute phase response is stimulated by diverse cytokines that activate either NF-κB or STAT3, we hypothesized that it could be eliminated by hepatocyte-specific interruption of both transcription factors. Here, we report that the elimination in mice of both NF-κB p65 (RelA) and STAT3, but neither alone, abrogated all acute phase responses measured. The failure to respond was consistent across multiple different infectious, inflammatory, and noxious stimuli, including pneumococcal pneumonia. When the effects of infection were analyzed in detail, pneumococcal pneumonia was found to alter the expression of over a thousand transcripts in the liver. This outcome was inhibited by the combined loss of RelA and STAT3. Moreover, this interruption of the acute phase response increased mortality and exacerbated bacterial dissemination during pneumonia, possibly as a result of acute humoral enhancement of macrophage opsonophagocytosis, which was impaired in the mutant mice. Thus, we conclude that RelA and STAT3 are essential for stress-induced transcriptional remodeling in the liver and the subsequent activation of the acute phase response, whose functional role includes compartmentalization of local infection.

Authors

Lee J. Quinton, Matthew T. Blahna, Matthew R. Jones, Eri Allen, Joseph D. Ferrari, Kristie L. Hilliard, Xiaoling Zhang, Vishakha Sabharwal, Hana Algül, Shizuo Akira, Roland M. Schmid, Stephen I. Pelton, Avrum Spira, Joseph P. Mizgerd

×

Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H
Elena Kudryashova, … , Irina Kramerova, Melissa J. Spencer
Elena Kudryashova, … , Irina Kramerova, Melissa J. Spencer
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1764-1776. https://doi.org/10.1172/JCI59581.
View: Text | PDF

Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H

  • Text
  • PDF
Abstract

Mutations in the E3 ubiquitin ligase tripartite motif-containing 32 (TRIM32) are responsible for the disease limb-girdle muscular dystrophy 2H (LGMD2H). Previously, we generated Trim32 knockout mice (Trim32–/– mice) and showed that they display a myopathic phenotype accompanied by neurogenic features. Here, we used these mice to investigate the muscle-specific defects arising from the absence of TRIM32, which underlie the myopathic phenotype. Using 2 models of induced atrophy, we showed that TRIM32 is dispensable for muscle atrophy. Conversely, TRIM32 was necessary for muscle regrowth after atrophy. Furthermore, TRIM32-deficient primary myoblasts underwent premature senescence and impaired myogenesis due to accumulation of PIAS4, an E3 SUMO ligase and TRIM32 substrate that was previously shown to be associated with senescence. Premature senescence of myoblasts was also observed in vivo in an atrophy/regrowth model. Trim32–/– muscles had substantially fewer activated satellite cells, increased PIAS4 levels, and growth failure compared with wild-type muscles. Moreover, Trim32–/– muscles exhibited features of premature sarcopenia, such as selective type II fast fiber atrophy. These results imply that premature senescence of muscle satellite cells is an underlying pathogenic feature of LGMD2H and reveal what we believe to be a new mechanism of muscular dystrophy associated with reductions in available satellite cells and premature sarcopenia.

Authors

Elena Kudryashova, Irina Kramerova, Melissa J. Spencer

×

Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model
Wei-Zhong Ying, … , Kristal J. Aaron, Paul W. Sanders
Wei-Zhong Ying, … , Kristal J. Aaron, Paul W. Sanders
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1777-1785. https://doi.org/10.1172/JCI46490.
View: Text | PDF

Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model

  • Text
  • PDF
Abstract

A common renal complication of multiple myeloma is “myeloma kidney,” a condition also known as cast nephropathy. The renal lesions (casts) are directly related to the production of monoclonal immunoglobulin free light chains (FLCs), which coprecipitate with Tamm-Horsfall glycoprotein (THP) in the lumen of the distal nephron, obstructing tubular fluid flow. Here, we report that analysis of the binding interaction between FLCs and THP demonstrates that the secondary structure and key amino acid residues on the complementarity-determining region 3 (CDR3) of FLCs are critically important determinants of the molecular interaction with THP. The findings permitted development of a cyclized competitor peptide that demonstrated strong inhibitory capability in the binding of FLCs to THP in vitro. When used in a rodent model of cast nephropathy, this cyclized peptide construct served as an effective inhibitor of intraluminal cast formation and prevented the functional manifestations of acute kidney injury in vivo. These experiments provide proof of concept that intraluminal cast formation is integrally involved in the pathogenesis of acute kidney injury from cast nephropathy. Further, the data support a clinically relevant approach to the management of renal failure in the setting of multiple myeloma.

Authors

Wei-Zhong Ying, Christopher E. Allen, Lisa M. Curtis, Kristal J. Aaron, Paul W. Sanders

×

Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice
Jimmy Rotolo, … , Wadih Arap, Richard Kolesnick
Jimmy Rotolo, … , Wadih Arap, Richard Kolesnick
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1786-1790. https://doi.org/10.1172/JCI59920.
View: Text | PDF Brief Report

Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice

  • Text
  • PDF
Abstract

Radiation gastrointestinal (GI) syndrome is a major lethal toxicity that may occur after a radiation/nuclear incident. Currently, there are no prophylactic countermeasures against radiation GI syndrome lethality for first responders, military personnel, or remediation workers entering a contaminated area. The pathophysiology of this syndrome requires depletion of stem cell clonogens (SCCs) within the crypts of Lieberkühn, which are a subset of cells necessary for postinjury regeneration of gut epithelium. Recent evidence indicates that SCC depletion is not exclusively a result of DNA damage but is critically coupled to ceramide-induced endothelial cell apoptosis within the mucosal microvascular network. Here we show that ceramide generated on the surface of endothelium coalesces to form ceramide-rich platforms that transmit an apoptotic signal. Moreover, we report the generation of 2A2, an anti-ceramide monoclonal antibody that binds to ceramide to prevent platform formation on the surface of irradiated endothelial cells of the murine GI tract. Consequently, we found that 2A2 protected against endothelial apoptosis in the small intestinal lamina propria and facilitated recovery of crypt SCCs, preventing the death of mice from radiation GI syndrome after high radiation doses. As such, we suggest that 2A2 represents a prototype of a new class of anti-ceramide therapeutics and an effective countermeasure against radiation GI syndrome mortality.

Authors

Jimmy Rotolo, Branka Stancevic, Jianjun Zhang, Guoqiang Hua, John Fuller, Xianglei Yin, Adriana Haimovitz-Friedman, Kisu Kim, Ming Qian, Marina Cardó-Vila, Zvi Fuks, Renata Pasqualini, Wadih Arap, Richard Kolesnick

×

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
Ulrike Harre, … , Pierre Jurdic, Georg Schett
Ulrike Harre, … , Pierre Jurdic, Georg Schett
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1791-1802. https://doi.org/10.1172/JCI60975.
View: Text | PDF

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

  • Text
  • PDF
Abstract

Autoimmunity is complicated by bone loss. In human rheumatoid arthritis (RA), the most severe inflammatory joint disease, autoantibodies against citrullinated proteins are among the strongest risk factors for bone destruction. We therefore hypothesized that these autoantibodies directly influence bone metabolism. Here, we found a strong and specific association between autoantibodies against citrullinated proteins and serum markers for osteoclast-mediated bone resorption in RA patients. Moreover, human osteoclasts expressed enzymes eliciting protein citrullination, and specific N-terminal citrullination of vimentin was induced during osteoclast differentiation. Affinity-purified human autoantibodies against mutated citrullinated vimentin (MCV) not only bound to osteoclast surfaces, but also led to robust induction of osteoclastogenesis and bone-resorptive activity. Adoptive transfer of purified human MCV autoantibodies into mice induced osteopenia and increased osteoclastogenesis. This effect was based on the inducible release of TNF-α from osteoclast precursors and the subsequent increase of osteoclast precursor cell numbers with enhanced expression of activation and growth factor receptors. Our data thus suggest that autoantibody formation in response to citrullinated vimentin directly induces bone loss, providing a link between the adaptive immune system and bone.

Authors

Ulrike Harre, Dan Georgess, Holger Bang, Aline Bozec, Roland Axmann, Elena Ossipova, Per-Johan Jakobsson, Wolfgang Baum, Falk Nimmerjahn, Eszter Szarka, Gabriella Sarmay, Grit Krumbholz, Elena Neumann, Rene Toes, Hans-Ulrich Scherer, Anca Irinel Catrina, Lars Klareskog, Pierre Jurdic, Georg Schett

×

Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D–induced inhibition of bone mineralization
Liesbet Lieben, … , Roger Bouillon, Geert Carmeliet
Liesbet Lieben, … , Roger Bouillon, Geert Carmeliet
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1803-1815. https://doi.org/10.1172/JCI45890.
View: Text | PDF

Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D–induced inhibition of bone mineralization

  • Text
  • PDF
Abstract

Serum calcium levels are tightly controlled by an integrated hormone-controlled system that involves active vitamin D [1,25(OH)2D], which can elicit calcium mobilization from bone when intestinal calcium absorption is decreased. The skeletal adaptations, however, are still poorly characterized. To gain insight into these issues, we analyzed the consequences of specific vitamin D receptor (Vdr) inactivation in the intestine and in mature osteoblasts on calcium and bone homeostasis. We report here that decreased intestinal calcium absorption in intestine-specific Vdr knockout mice resulted in severely reduced skeletal calcium levels so as to ensure normal levels of calcium in the serum. Furthermore, increased 1,25(OH)2D levels not only stimulated bone turnover, leading to osteopenia, but also suppressed bone matrix mineralization. This resulted in extensive hyperosteoidosis, also surrounding the osteocytes, and hypomineralization of the entire bone cortex, which may have contributed to the increase in bone fractures. Mechanistically, osteoblastic VDR signaling suppressed calcium incorporation in bone by directly stimulating the transcription of genes encoding mineralization inhibitors. Ablation of skeletal Vdr signaling precluded this calcium transfer from bone to serum, leading to better preservation of bone mass and mineralization. These findings indicate that in mice, maintaining normocalcemia has priority over skeletal integrity, and that to minimize skeletal calcium storage, 1,25(OH)2D not only increases calcium release from bone, but also inhibits calcium incorporation in bone.

Authors

Liesbet Lieben, Ritsuko Masuyama, Sophie Torrekens, Riet Van Looveren, Jan Schrooten, Pieter Baatsen, Marie-Hélène Lafage-Proust, Tom Dresselaers, Jian Q. Feng, Lynda F. Bonewald, Mark B. Meyer, J. Wesley Pike, Roger Bouillon, Geert Carmeliet

×

CD4+ T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease
Antonella De Luca, … , Jean-Paul Latgé, Luigina Romani
Antonella De Luca, … , Jean-Paul Latgé, Luigina Romani
Published April 23, 2012
Citation Information: J Clin Invest. 2012;122(5):1816-1831. https://doi.org/10.1172/JCI60862.
View: Text | PDF

CD4+ T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease

  • Text
  • PDF
Abstract

Aspergillus fumigatus is a model fungal pathogen and a common cause of infection in individuals with the primary immunodeficiency chronic granulomatous disease (CGD). Although primarily considered a deficiency of innate immunity, CGD is also linked to dysfunctional T cell reactivity. Both CD4+ and CD8+ T cells mediate vaccine-induced protection from experimental aspergillosis, but the molecular mechanisms leading to the generation of protective immunity and whether these mechanisms are dysregulated in individuals with CGD have not been determined. Here, we show that activation of either T cell subset in a mouse model of CGD is contingent upon the nature of the fungal vaccine, the involvement of distinct innate receptor signaling pathways, and the mode of antigen routing and presentation in DCs. Aspergillus conidia activated CD8+ T cells upon sorting to the Rab14+ endosomal compartment required for alternative MHC class I presentation. Cross-priming of CD8+ T cells failed to occur in mice with CGD due to defective DC endosomal alkalinization and autophagy. However, long-lasting antifungal protection and disease control were successfully achieved upon vaccination with purified fungal antigens that activated CD4+ T cells through the endosome/lysosome pathway. Our study thus indicates that distinct intracellular pathways are exploited for the priming of CD4+ and CD8+ T cells to A. fumigatus and suggests that CD4+ T cell vaccination may be able to overcome defective antifungal CD8+ T cell memory in individuals with CGD.

Authors

Antonella De Luca, Rossana G. Iannitti, Silvia Bozza, Remi Beau, Andrea Casagrande, Carmen D’Angelo, Silvia Moretti, Cristina Cunha, Gloria Giovannini, Cristina Massi-Benedetti, Agostinho Carvalho, Louis Boon, Jean-Paul Latgé, Luigina Romani

×

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
Federica Maione, … , Guido Serini, Enrico Giraudo
Federica Maione, … , Guido Serini, Enrico Giraudo
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1832-1848. https://doi.org/10.1172/JCI58976.
View: Text | PDF

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice

  • Text
  • PDF
Abstract

Cancer development, progression, and metastasis are highly dependent on angiogenesis. The use of antiangiogenic drugs has been proposed as a novel strategy to interfere with tumor growth, but cancer cells respond by developing strategies to escape these treatments. In particular, animal models show that antiangiogenic drugs currently used in clinical settings reduce tumor tissue oxygenation and trigger molecular events that foster cancer resistance to therapy. Here, we show that semaphorin 3A (Sema3A) expression overcomes the proinvasive and prometastatic resistance observed upon angiogenesis reduction by the small-molecule tyrosine inhibitor sunitinib in both pancreatic neuroendocrine tumors (PNETs) in RIP-Tag2 mice and cervical carcinomas in HPV16/E2 mice. By improving cancer tissue oxygenation and extending the normalization window, Sema3A counteracted sunitinib-induced activation of HIF-1α, Met tyrosine kinase receptor, epithelial-mesenchymal transition (EMT), and other hypoxia-dependent signaling pathways. Sema3A also reduced tumor hypoxia and halted cancer dissemination induced by DC101, a specific inhibitor of the VEGF pathway. As a result, reexpressing Sema3A in cancer cells converts metastatic PNETs and cervical carcinomas into benign lesions. We therefore suggest that this strategy could be developed to safely harnesses the therapeutic potential of the antiangiogenic treatment.

Authors

Federica Maione, Stefania Capano, Donatella Regano, Lorena Zentilin, Mauro Giacca, Oriol Casanovas, Federico Bussolino, Guido Serini, Enrico Giraudo

×

Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
Toni Celià-Terrassa, … , Pedro L. Fernández, Timothy M. Thomson
Toni Celià-Terrassa, … , Pedro L. Fernández, Timothy M. Thomson
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1849-1868. https://doi.org/10.1172/JCI59218.
View: Text | PDF

Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells

  • Text
  • PDF
Abstract

Malignant progression in cancer requires populations of tumor-initiating cells (TICs) endowed with unlimited self renewal, survival under stress, and establishment of distant metastases. Additionally, the acquisition of invasive properties driven by epithelial-mesenchymal transition (EMT) is critical for the evolution of neoplastic cells into fully metastatic populations. Here, we characterize 2 human cellular models derived from prostate and bladder cancer cell lines to better understand the relationship between TIC and EMT programs in local invasiveness and distant metastasis. The model tumor subpopulations that expressed a strong epithelial gene program were enriched in highly metastatic TICs, while a second subpopulation with stable mesenchymal traits was impoverished in TICs. Constitutive overexpression of the transcription factor Snai1 in the epithelial/TIC-enriched populations engaged a mesenchymal gene program and suppressed their self renewal and metastatic phenotypes. Conversely, knockdown of EMT factors in the mesenchymal-like prostate cancer cell subpopulation caused a gain in epithelial features and properties of TICs. Both tumor cell subpopulations cooperated so that the nonmetastatic mesenchymal-like prostate cancer subpopulation enhanced the in vitro invasiveness of the metastatic epithelial subpopulation and, in vivo, promoted the escape of the latter from primary implantation sites and accelerated their metastatic colonization. Our models provide new insights into how dynamic interactions among epithelial, self-renewal, and mesenchymal gene programs determine the plasticity of epithelial TICs.

Authors

Toni Celià-Terrassa, Óscar Meca-Cortés, Francesca Mateo, Alexia Martínez de Paz, Nuria Rubio, Anna Arnal-Estapé, Brian J. Ell, Raquel Bermudo, Alba Díaz, Marta Guerra-Rebollo, Juan José Lozano, Conchi Estarás, Catalina Ulloa, Daniel ρlvarez-Simón, Jordi Milà, Ramón Vilella, Rosanna Paciucci, Marian Martínez-Balbás, Antonio García de Herreros, Roger R. Gomis, Yibin Kang, Jerónimo Blanco, Pedro L. Fernández, Timothy M. Thomson

×

ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion
Weiwen Long, … , Ming-Jer Tsai, Bert W. O’Malley
Weiwen Long, … , Ming-Jer Tsai, Bert W. O’Malley
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1869-1880. https://doi.org/10.1172/JCI61492.
View: Text | PDF

ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion

  • Text
  • PDF
Abstract

In contrast to the well-studied classic MAPKs, such as ERK1/2, little is known concerning the regulation and substrates of the atypical MAPK ERK3 signaling cascade and its function in cancer progression. Here, we report that ERK3 interacted with and phosphorylated steroid receptor coactivator 3 (SRC-3), an oncogenic protein overexpressed in multiple human cancers at serine 857 (S857). This ERK3-mediated phosphorylation at S857 was essential for interaction of SRC-3 with the ETS transcription factor PEA3, which promotes upregulation of MMP gene expression and proinvasive activity in lung cancer cells. Importantly, knockdown of ERK3 or SRC-3 inhibited the ability of lung cancer cells to invade and form tumors in the lung in a xenograft mouse model. In addition, ERK3 was found to be highly upregulated in human lung carcinomas. Our study identifies a previously unknown role for ERK3 in promoting lung cancer cell invasiveness by phosphorylating SRC-3 and regulating SRC-3 proinvasive activity by site-specific phosphorylation. As such, ERK3 protein kinase may be an attractive target for therapeutic treatment of invasive lung cancer.

Authors

Weiwen Long, Charles E. Foulds, Jun Qin, Jian Liu, Chen Ding, David M. Lonard, Luisa M. Solis, Ignacio I. Wistuba, Jun Qin, Sophia Y. Tsai, Ming-Jer Tsai, Bert W. O’Malley

×

Aberrant nuclear localization of EBP50 promotes colorectal carcinogenesis in xenotransplanted mice by modulating TCF-1 and β-catenin interactions
Yu-Yu Lin, … , Chi-Ling Chen, Tzuu-Shuh Jou
Yu-Yu Lin, … , Chi-Ling Chen, Tzuu-Shuh Jou
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1881-1894. https://doi.org/10.1172/JCI45661.
View: Text | PDF

Aberrant nuclear localization of EBP50 promotes colorectal carcinogenesis in xenotransplanted mice by modulating TCF-1 and β-catenin interactions

  • Text
  • PDF
Abstract

Dysregulation of canonical Wnt signaling is thought to play a role in colon carcinogenesis. β-Catenin, a key mediator of the pathway, is stabilized upon Wnt activation and accumulates in the nucleus, where it can interact with the transcription factor T cell factor (TCF) to transactivate gene expression. Normal colonic epithelia express a truncated TCF-1 form, called dnTCF-1, that lacks the critical β-catenin–binding domain and behaves as a transcriptional suppressor. How the cell maintains a balance between the two forms of TCF-1 is unclear. Here, we show that ERM-binding phosphoprotein 50 (EBP50) modulates the interaction between β-catenin and TCF-1. We observed EBP50 localization to the nucleus of human colorectal carcinoma cell lines at low cell culture densities and human primary colorectal tumors that manifested a poor clinical outcome. In contrast, EBP50 was primarily membranous in confluent cell lines. Aberrantly located EBP50 stabilized conventional β-catenin/TCF-1 complexes and connected β-catenin to dnTCF-1 to form a ternary molecular complex that enhanced Wnt/β-catenin signaling events, including the transcription of downstream oncogenes such as c-Myc and cyclin D1. Genome-wide analysis of the EBP50 occupancy pattern revealed consensus binding motifs bearing similarity to Wnt-responsive element. Conventional chromatin immunoprecipitation assays confirmed that EBP50 bound to genomic regions highly enriched with TCF/LEF binding motifs. Knockdown of EBP50 in human colorectal carcinoma cell lines compromised cell cycle progression, anchorage-independent growth, and tumorigenesis in nude mice. We therefore suggest that nuclear EBP50 facilitates colon tumorigenesis by modulating the interaction between β-catenin and TCF-1.

Authors

Yu-Yu Lin, Yung-Ho Hsu, Hsin-Yi Huang, Yih-Jyh Shann, Chi-Ying F. Huang, Shu-Chen Wei, Chi-Ling Chen, Tzuu-Shuh Jou

×

SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer
Chu-An Wang, … , J. Chuck Harrell, Heide L. Ford
Chu-An Wang, … , J. Chuck Harrell, Heide L. Ford
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1895-1906. https://doi.org/10.1172/JCI59858.
View: Text | PDF

SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer

  • Text
  • PDF
Abstract

An association between lymph node metastasis and poor prognosis in breast cancer was observed decades ago. However, the mechanisms by which tumor cells infiltrate the lymphatic system are not completely understood. Recently, it has been proposed that the lymphatic system has an active role in metastatic dissemination and that tumor-secreted growth factors stimulate lymphangiogenesis. We therefore investigated whether SIX1, a homeodomain-containing transcription factor previously associated in breast cancer with lymph node positivity, was involved in lymphangiogenesis and lymphatic metastasis. In a model in which human breast cancer cells were injected into immune-compromised mice, we found that SIX1 expression promoted peritumoral and intratumoral lymphangiogenesis, lymphatic invasion, and distant metastasis of breast cancer cells. SIX1 induced transcription of the prolymphangiogenic factor VEGF-C, and this was required for lymphangiogenesis and lymphatic metastasis. Using a mouse mammary carcinoma model, we found that VEGF-C was not sufficient to mediate all the metastatic effects of SIX1, indicating that SIX1 acts through additional, VEGF-C–independent pathways. Finally, we verified the clinical significance of this prometastatic SIX1/VEGF-C axis by demonstrating coexpression of SIX1 and VEGF-C in human breast cancer. These data define a critical role for SIX1 in lymphatic dissemination of breast cancer cells, providing a direct mechanistic explanation for how VEGF-C expression is upregulated in breast cancer, resulting in lymphangiogenesis and metastasis.

Authors

Chu-An Wang, Paul Jedlicka, Aaron N. Patrick, Douglas S. Micalizzi, Kimberly C. Lemmer, Erin Deitsch, Matias Casás-Selves, J. Chuck Harrell, Heide L. Ford

×

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis
Philip D. Anderson, … , Isam-Eldin Eltoum, Sarki A. Abdulkadir
Philip D. Anderson, … , Isam-Eldin Eltoum, Sarki A. Abdulkadir
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1907-1919. https://doi.org/10.1172/JCI58540.
View: Text | PDF

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis

  • Text
  • PDF
Abstract

Cooperativity between oncogenic mutations is recognized as a fundamental feature of malignant transformation, and it may be mediated by synergistic regulation of the expression of pro- and antitumorigenic target genes. However, the mechanisms by which oncogenes and tumor suppressors coregulate downstream targets and pathways remain largely unknown. Here, we used ChIP coupled to massively parallel sequencing (ChIP-seq) and gene expression profiling in mouse prostates to identify direct targets of the tumor suppressor Nkx3.1. Further analysis indicated that a substantial fraction of Nkx3.1 target genes are also direct targets of the oncoprotein Myc. We also showed that Nkx3.1 and Myc bound to and crossregulated shared target genes in mouse and human prostate epithelial cells and that Nkx3.1 could oppose the transcriptional activity of Myc. Furthermore, loss of Nkx3.1 cooperated with concurrent overexpression of Myc to promote prostate cancer in transgenic mice. In human prostate cancer patients, dysregulation of shared NKX3.1/MYC target genes was associated with disease relapse. Our results indicate that NKX3.1 and MYC coregulate prostate tumorigenesis by converging on, and crossregulating, a common set of target genes. We propose that coregulation of target gene expression by oncogenic/tumor suppressor transcription factors may represent a general mechanism underlying the cooperativity of oncogenic mutations during tumorigenesis.

Authors

Philip D. Anderson, Sydika A. McKissic, Monica Logan, Meejeon Roh, Omar E. Franco, Jie Wang, Irina Doubinskaia, Riet van der Meer, Simon W. Hayward, Christine M. Eischen, Isam-Eldin Eltoum, Sarki A. Abdulkadir

×

Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer
Karim Nacerddine, … , Shridar Ganesan, Maarten van Lohuizen
Karim Nacerddine, … , Shridar Ganesan, Maarten van Lohuizen
Published April 16, 2012
Citation Information: J Clin Invest. 2012;122(5):1920-1932. https://doi.org/10.1172/JCI57477.
View: Text | PDF

Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer

  • Text
  • PDF
Abstract

Prostate cancer (PCa) is a major lethal malignancy in men, but the molecular events and their interplay underlying prostate carcinogenesis remain poorly understood. Epigenetic events and the upregulation of polycomb group silencing proteins including Bmi1 have been described to occur during PCa progression. Here, we found that conditional overexpression of Bmi1 in mice induced prostatic intraepithelial neoplasia, and elicited invasive adenocarcinoma when combined with PTEN haploinsufficiency. In addition, Bmi1 and the PI3K/Akt pathway were coactivated in a substantial fraction of human high-grade tumors. We found that Akt mediated Bmi1 phosphorylation, enhancing its oncogenic potential in an Ink4a/Arf-independent manner. This process also modulated the DNA damage response and affected genomic stability. Together, our findings demonstrate the etiological role of Bmi1 in PCa, unravel an oncogenic collaboration between Bmi1 and the PI3K/Akt pathway, and provide mechanistic insights into the modulation of Bmi1 function by phosphorylation during prostate carcinogenesis.

Authors

Karim Nacerddine, Jean-Bernard Beaudry, Vasudeva Ginjala, Bart Westerman, Francesca Mattiroli, Ji-Ying Song, Henk van der Poel, Olga Balagué Ponz, Colin Pritchard, Paulien Cornelissen-Steijger, John Zevenhoven, Ellen Tanger, Titia K. Sixma, Shridar Ganesan, Maarten van Lohuizen

×

MyD88 is critically involved in immune tolerance breakdown at environmental interfaces of Foxp3-deficient mice
Magali Noval Rivas, … , Greg Lawson, Talal A. Chatila
Magali Noval Rivas, … , Greg Lawson, Talal A. Chatila
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(5):1933-1947. https://doi.org/10.1172/JCI40591.
View: Text | PDF

MyD88 is critically involved in immune tolerance breakdown at environmental interfaces of Foxp3-deficient mice

  • Text
  • PDF
Abstract

Tregs expressing the transcription factor Foxp3 suppress self-reactive T cells, prevent autoimmunity, and help contain immune responses to foreign antigens, thereby limiting the potential for inadvertent tissue damage. Mutations in the FOXP3 gene result in Treg deficiency in mice and humans, which leads to the development of a multisystem autoimmune inflammatory disease. The contribution of dysregulated innate immune responses to the pathogenesis of Foxp3 deficiency disease is unknown. In this study, we examined the role of microbial signals in the pathogenesis of Foxp3 deficiency disease by studying Foxp3 mutant mice that had concurrent deficiencies in TLR signaling pathways. Global deficiency of the common TLR adaptor MyD88 offered partial protection from Foxp3 deficiency disease. Specifically, it protected from disease at the environmental interfaces of the skin, lungs, and gut. In contrast, systemic disease, in the form of unrestrained lymphoproliferation, continued unabated. The effect of MyD88 deficiency at environmental interfaces involved the disruption of chemokine gradients that recruit effector T cells and DCs, resulting in their entrapment in secondary lymphoid tissues. These results suggests that Tregs have a key role in maintaining tolerance at host-microbial interfaces by restraining tonic MyD88-dependent proinflammatory signals. Moreover, microbial factors may play a substantial role in the pathogenesis of human autoimmune disease resulting from Treg deficiency.

Authors

Magali Noval Rivas, Yi T. Koh, Andrew Chen, Annie Nguyen, Young Ho Lee, Greg Lawson, Talal A. Chatila

×
Corrigenda
Administration of BMP2/7 in utero partially reverses Rubinstein-Taybi syndrome–like skeletal defects induced by Pdk1 or Cbp mutations in mice
Jae-Hyuck Shim, … , Vivienne I. Rebel, Laurie H. Glimcher
Jae-Hyuck Shim, … , Vivienne I. Rebel, Laurie H. Glimcher
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1948-1948. https://doi.org/10.1172/JCI63413.
View: Text | PDF | Amended Article

Administration of BMP2/7 in utero partially reverses Rubinstein-Taybi syndrome–like skeletal defects induced by Pdk1 or Cbp mutations in mice

  • Text
  • PDF
Abstract

Authors

Jae-Hyuck Shim, Matthew B. Greenblatt, Anju Singh, Nicholas Brady, Dorothy Hu, Rebecca Drapp, Wataru Ogawa, Masato Kasuga, Tetsuo Noda, Sang-Hwa Yang, Sang-Kyou Lee, Vivienne I. Rebel, Laurie H. Glimcher

×

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice
Aubrey C. Chan, … , Kevin J. Whitehead, Dean Y. Li
Aubrey C. Chan, … , Kevin J. Whitehead, Dean Y. Li
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1948-1948. https://doi.org/10.1172/JCI63474.
View: Text | PDF | Amended Article

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice

  • Text
  • PDF
Abstract

Authors

Aubrey C. Chan, Stavros G. Drakos, Oscar E. Ruiz, Alexandra C.H. Smith, Christopher C. Gibson, Jing Ling, Samuel F. Passi, Amber N. Stratman, Anastasia Sacharidou, M. Patricia Revelo, Allie H. Grossmann, Nikolaos A. Diakos, George E. Davis, Mark M. Metzstein, Kevin J. Whitehead, Dean Y. Li

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts